{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "active-ingredient", "type": "clause", "offset": [9, 26]}, {"key": "direct-effect", "type": "definition", "offset": [89, 102]}, {"key": "the-human", "type": "clause", "offset": [221, 230]}], "snippet": "means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.", "samples": [{"hash": "9vgkDdXwpUh", "uri": "/contracts/9vgkDdXwpUh#drug-substance", "label": "Master Services Agreement (Apogee Therapeutics, Inc.)", "score": 36.3593444824, "published": true}, {"hash": "7bvNWT9mtsy", "uri": "/contracts/7bvNWT9mtsy#drug-substance", "label": "Master Development Services Agreement (Yumanity Therapeutics, Inc.)", "score": 33.752910614, "published": true}, {"hash": "6B2mBoQhyE4", "uri": "/contracts/6B2mBoQhyE4#drug-substance", "label": "Master Services Agreement (CytoDyn Inc.)", "score": 30.6153316498, "published": true}], "size": 16, "hash": "2daa21384e9acfa899e058dc2a1b9f55", "id": 1}, {"snippet_links": [{"key": "client-product", "type": "definition", "offset": [11, 25]}, {"key": "dosage-form", "type": "definition", "offset": [74, 85]}], "snippet": "means bulk Client Product, which has not yet been packaged into its final dosage form.", "samples": [{"hash": "9sJW5bIpXex", "uri": "/contracts/9sJW5bIpXex#drug-substance", "label": "Cell Line License Agreement (Cyclerion Therapeutics, Inc.)", "score": 37.4353179932, "published": true}, {"hash": "88mBI3Z5b15", "uri": "/contracts/88mBI3Z5b15#drug-substance", "label": "Cell Line License Agreement (Glycomimetics Inc)", "score": 36.2553062439, "published": true}, {"hash": "bgqDphwfa5d", "uri": "/contracts/bgqDphwfa5d#drug-substance", "label": "Cell Line License Agreement (Oruka Therapeutics, Inc.)", "score": 36.175907135, "published": true}], "size": 11, "hash": "bffbf7dacf082e1a29e88511bc8efe47", "id": 2}, {"snippet_links": [{"key": "drug-product", "type": "definition", "offset": [49, 61]}], "snippet": "means the Compound component of a pharmaceutical drug product.", "samples": [{"hash": "l56C2UjVrbA", "uri": "/contracts/l56C2UjVrbA#drug-substance", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 36.8658447266, "published": true}, {"hash": "dcKatfS98Yw", "uri": "/contracts/dcKatfS98Yw#drug-substance", "label": "Technology Transfer and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 32.364818573, "published": true}, {"hash": "kscJ3uR9ka8", "uri": "/contracts/kscJ3uR9ka8#drug-substance", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 29.848733902, "published": true}], "size": 10, "hash": "60243430968ce3b73a3bbecf797638e2", "id": 3}, {"snippet_links": [{"key": "bulk-drug-substance", "type": "definition", "offset": [6, 25]}, {"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [123, 155]}], "snippet": "means bulk drug substance that is represented for use in a drug that, when used in the Manufacturing of a drug, becomes an active pharmaceutical ingredient.", "samples": [{"hash": "hlLObtcT6jo", "uri": "/contracts/hlLObtcT6jo#drug-substance", "label": "Collaboration and License Agreement (Spruce Biosciences, Inc.)", "score": 36.2854194641, "published": true}, {"hash": "BxlyFPv0n6", "uri": "/contracts/BxlyFPv0n6#drug-substance", "label": "Collaboration and License Agreement (Inovio Pharmaceuticals, Inc.)", "score": 32.603012085, "published": true}, {"hash": "77XK8h2KE5v", "uri": "/contracts/77XK8h2KE5v#drug-substance", "label": "Collaboration and License Agreement (Inovio Pharmaceuticals, Inc.)", "score": 32.1622161865, "published": true}], "size": 6, "hash": "0d6c17604bf7c2cdc43e26f1d8b5454a", "id": 4}, {"snippet_links": [{"key": "chemical-substance", "type": "definition", "offset": [10, 28]}, {"key": "generic-name", "type": "definition", "offset": [69, 81]}, {"key": "code-number", "type": "definition", "offset": [83, 94]}], "snippet": "means the chemical substance identified as faropenem daloxate as its generic name (code number: SUN A0026) and having the chemical structure: (5-Methyl-2-oxo-1, 3-dioxolen-4-yl) methyl (5R, 6S)-6-[(R)-1-hydroxyethyl]-2-[(R)-2-tetrahydro-furyl] penem-3-carboxylate.", "samples": [{"hash": "kcBk8qU0j0O", "uri": "/contracts/kcBk8qU0j0O#drug-substance", "label": "Supply Agreement (Replidyne Inc)", "score": 21.0, "published": true}, {"hash": "kJuXrcq3Hw8", "uri": "/contracts/kJuXrcq3Hw8#drug-substance", "label": "License Agreement (Replidyne Inc)", "score": 21.0, "published": true}, {"hash": "aJJCbSQmakp", "uri": "/contracts/aJJCbSQmakp#drug-substance", "label": "License Agreement (Replidyne Inc)", "score": 21.0, "published": true}], "size": 6, "hash": "37a9979bc5d0b77dd79682ecf5a653d8", "id": 5}, {"snippet_links": [{"key": "other-product", "type": "definition", "offset": [67, 80]}, {"key": "work-order", "type": "definition", "offset": [97, 107]}], "snippet": "or \u201cDS\u201d means the bulk purified recombinant protein DX-2930 or any other product as defined in a Work Order that is produced by cell culture and purification process from a MCB or WCB.", "samples": [{"hash": "5HoqvoUW7nG", "uri": "/contracts/5HoqvoUW7nG#drug-substance", "label": "Master Development & Manufacturing Services Agreement (Dyax Corp)", "score": 27.0342235565, "published": true}, {"hash": "bnDAwiW2zJE", "uri": "/contracts/bnDAwiW2zJE#drug-substance", "label": "Master Development & Manufacturing Services Agreement (Dyax Corp)", "score": 26.8453121185, "published": true}], "size": 6, "hash": "34fc5fe6bf4f27375a8d3bb6fa814e87", "id": 6}, {"snippet_links": [{"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [10, 42]}], "snippet": "means the active pharmaceutical ingredient.", "samples": [{"hash": "72seS1H82Gs", "uri": "/contracts/72seS1H82Gs#drug-substance", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 30.8261470795, "published": true}, {"hash": "lRoAteVMpjC", "uri": "/contracts/lRoAteVMpjC#drug-substance", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 21.1724853516, "published": true}], "size": 6, "hash": "763ccd31c24053fa8ebf2a67412ba3cb", "id": 7}, {"snippet_links": [{"key": "the-license-agreement", "type": "clause", "offset": [31, 52]}], "snippet": "means bulk BIWI1 as defined in the License Agreement.", "samples": [{"hash": "lWHLTI7W596", "uri": "/contracts/lWHLTI7W596#drug-substance", "label": "Development and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}, {"hash": "aL2DELmhiBh", "uri": "/contracts/aL2DELmhiBh#drug-substance", "label": "Development and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}, {"hash": "ekeKsnGZkwa", "uri": "https://investor.immunogen.com/static-files/d3ed8a98-6b6d-4904-ad98-0ee3f42ca9b0", "label": "Amendment", "score": 13.965092659, "published": false}], "size": 5, "hash": "0ca96b4cd64394c9b3c874513f9fb5df", "id": 8}, {"snippet_links": [], "snippet": "means the collagenases derived from Clostridium histolyticum.", "samples": [{"hash": "dCngcCKmyBl", "uri": "/contracts/dCngcCKmyBl#drug-substance", "label": "Collaboration Agreement (Auxilium Pharmaceuticals Inc)", "score": 24.5811080933, "published": true}, {"hash": "iaXyK7IfZFB", "uri": "/contracts/iaXyK7IfZFB#drug-substance", "label": "Collaboration Agreement (Auxilium Pharmaceuticals Inc)", "score": 23.3545513153, "published": true}, {"hash": "8MvY3EHGw51", "uri": "/contracts/8MvY3EHGw51#drug-substance", "label": "Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)", "score": 22.3524990082, "published": true}], "size": 5, "hash": "e1b38c00be6352871dfbe7aa73c2c944", "id": 9}, {"snippet_links": [{"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [10, 42]}, {"key": "chemical-compound", "type": "definition", "offset": [51, 68]}, {"key": "by-takeda", "type": "clause", "offset": [75, 84]}, {"key": "on-schedule", "type": "definition", "offset": [133, 144]}, {"key": "the-license-agreement", "type": "clause", "offset": [154, 175]}, {"key": "the-specifications", "type": "definition", "offset": [182, 200]}, {"key": "section-71", "type": "definition", "offset": [253, 264]}, {"key": "for-clarity", "type": "clause", "offset": [273, 284]}, {"key": "clinical-manufacturing-and-supply-agreement", "type": "definition", "offset": [334, 377]}], "snippet": "means the active pharmaceutical ingredient for the chemical compound coded by Takeda as TAK-385, the structure of which is set forth on Schedule 1.138 of the License Agreement, with the Specifications (as defined below), and is Manufactured pursuant to Section 7.1 hereof. For clarity, such pharmaceutical ingredient under the Takeda Clinical Manufacturing and Supply Agreement shall not be included herein.", "samples": [{"hash": "eaAtR5hzg3s", "uri": "/contracts/eaAtR5hzg3s#drug-substance", "label": "Commercial Manufacturing & Supply Agreement (Myovant Sciences Ltd.)", "score": 32.3566055298, "published": true}, {"hash": "fZi5lL2nBCa", "uri": "/contracts/fZi5lL2nBCa#drug-substance", "label": "Commercial Manufacturing & Supply Agreement (Myovant Sciences Ltd.)", "score": 29.7091026306, "published": true}, {"hash": "gxPqvMFEGm5", "uri": "/contracts/gxPqvMFEGm5#drug-substance", "label": "Commercial Manufacturing & Supply Agreement (Myovant Sciences Ltd.)", "score": 29.5968513489, "published": true}], "size": 5, "hash": "74257f5ffc8f5665dfea5a7ef2825af0", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXZHJ1Zy1zdWJzdGFuY2UjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.", "title": "Drug Substance", "size": 423, "id": "drug-substance", "examples": ["Included within this forecast, [***] (\u201cBinding Period\u201d) giving details of volume requirements for the Products (in respect of <strong>Drug Substance</strong> and Drug Product as applicable) required to be Manufactured, or such shorter period as may then remain under the Term (the \u201cForecast Schedule\u201d).", "WuXi Biologics shall invoice Client for [***] of the Price for each Batch of Products ordered under a Purchase Order upon commencement (based on vial thaw in case of <strong>Drug Substance</strong> and bulk <strong>Drug Substance</strong> bag thaw in case of Drug Product) of Manufacturing of the Products."], "related": [["bulk-drug-substance", "Bulk drug substance", "Bulk <strong>drug substance</strong>"], ["finished-product", "Finished Product", "Finished Product"], ["bulk-product", "Bulk Product", "Bulk Product"], ["drug-product", "Drug Product", "Drug Product"], ["api", "API", "API"]], "related_snippets": [], "updated": "2026-08-08T05:41:39+00:00"}, "json": true, "cursor": ""}}